Industry executives expected a second Trump administration to reduce regulation for drug companies, but alarming health policy nominees threaten to shift this perception drastically.
Robert F. Kennedy Jr., chosen as health secretary, is a longtime vaccine skeptic and has publicly accused drug companies of mass poisoning, raising concerns for pharmaceutical executives.
Dr. Dave Weldon, Trump's CDC pick, has previously pushed to move vaccine safety research away from the agency, causing further disquiet among drug makers regarding regulatory changes.
Dr. Mehmet Oz, nominated for the Centers for Medicare and Medicaid Services, lacks substantial experience in managing large health care bureaucracies, prompting skepticism about his capability.
#trump-administration #pharmaceutical-industry #health-policy #vaccine-skepticism #regulatory-changes
Collection
[
|
...
]